First in Human Study for Safety and Tolerability of AL003.

Summary

This is a multi-center, randomized, double-blind, placebo-controlled, dose escalation first in human (FIH) study in healthy adults and in patients with mild to moderate Alzheimer's disease. The study is designed to systematically assess the safety (including immunogenicity) and tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of AL003.

Timeline

Start

2019-03-29

Primary completion

2021-05-06

Completion

2021-05-06

Drugs

Indications